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‘The Emperor’s New Clothes’ is the title of a famous fairy
tale from the Danish writer Hans Christian Andersen
(1805–75). Two weavers promised an Emperor a splendid
suit of clothes, supposedly invisible to those unfit for their
positions, stupid or incompetent. When the Emperor
paraded before his subjects in his new clothes, a child said:
‘But he isn’t wearing anything at all!’ This was whispered
from person to person until everyone in the crowd was
shouting that the emperor had nothing on. The emperor
heard it, but held his head high and finished the procession.
FROM SYMPLICITY HTN-2 TO SYMPLICITY
HTN-3 : A PREDICTABLE FAILURE
The Symplicity studies [1–3] demonstrated the feasibility of
catheter-based endovascular sympathetic renal denervation
(RDN) in drug-resistant hypertension. In Symplicity HTN-2,
the first randomized trial testing the efficacy and safety of
RDN plus medical treatment versus medical treatment only,
blood pressure (BP) decreased by 32/12 mmHg (P < 0.0001) in
the RDN-treated group, whereas it remained unchanged in the
control group (1/0 mmHg, P≥ 0.77) [2]. No serious pro-
cedure-related or device-related complications occurred, and
the incidence of adverse events was similar in both groups [2].
The Symplicity HTN-2 trial was small (∼50 patients/group),
with short-term follow-up (6 months), and the primary end-
point was based on an unblinded assessment of office rather
than 24-h ambulatory BP [2], which is the gold standard.
In the accompanying editorial, Doumas and Doumas [4] em-
phasized additional limitations of the trial, including the lack
of per-protocol exclusion of white-coat and secondary
hypertension, the variable and unpredictable BP response and
the low overall rate of BP control after RDN (39%) [4]. Accord-
ing to the Editorialists, RDN might evolve into a novel treat-
ment modality of hypertension but ‘the jury was still out’ [4].
Despite this wise statement, RDN was rapidly and aggres-
sively promoted as an established treatment of drug-resistant
hypertension. Dozens of editorial and reviews were published,
most of which were pure eulogies, without critical or balanced
assessment of the existing evidence. The Symplicity investi-
gators themselves questioned the interest of identifying re-
sponder profiles [3]. Allegedly, with an underlying 90%
response rate in conjunction with the low observed morbidity
[3], RDN was to be applied indiscriminately to all patients
with resistant hypertension. Based on shaky evidence derived
from a single short-term randomized trial with unblinded
endpoint assessment [2], the speculation was that RDN ‘could
potentially help alleviate some of the $500 billion impact that
hypertension has on our health care systems by reducing or
eliminating costly and lifelong medication use’ [5] and phar-
maco-economic models were hastily elaborated to demonstrate
the cost-effectiveness of the technique [6–7]. The hype gener-
ated by the Simplicity studies [1–3] prompted >10 companies
to engage in the footsteps of Ardian–Medtronic® and to develop
their own RDN system, five of which obtained the CE mark (http
://en.wikipedia.org/wiki/Renal_sympathetic_denervation). While
RDN remained an experimental procedure in the USA,
pending the results of Symplicity HTN-3 [8] (NCT01418261),
a large randomized controlled trial including a sham pro-
cedure, reimbursement of RDN was granted in Germany, Aus-
tralia, the Netherlands, Switzerland and Sweden, leading to an
outburst in the number of procedures performed (>5000 world-
wide, of which 600 in a single German centre) (http://
www.spiegel.de/spiegel/print/d-102241746.html). RDN was
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hypertension [9], isolated systolic hypertension [10], stenotic [11]
or stented [12] renal arteries and even in a patient with
Münchausen syndrome [13]. Finally, based almost exclusively
on observational, small studies, RDN was proposed as a poten-
tial treatment in a host of medical conditions, including
chronic kidney disease, atrial fibrillation, heart failure, obstruc-
tive sleep apnoea, metabolic syndrome and polycystic ovary
syndrome [14].
While dissenting voices [5, 15] remained almost unheard in
the triumphal symphony of RDN, the first cautionary message
came with the presentation and subsequent publication [16] of
a patient-level meta-analysis, including BP results obtained in
109 patients with resistant hypertension who underwent RDN
within the European Network COordinating research on
Renal Denervation (ENCOReD). Six months after RDN,
office BP decreased by 14.2/6.5 mmHg and 24-h BP by only
5.2/3.1 mmHg (baseline and centre-adjusted results, P < 0.001
for both). Pill burden remained virtually unchanged (number
of antihypertensive drugs: 4.4 versus 4.7 at baseline, P = 0.001).
Individual BP responses were highly variable, with more than
one-third of patients showing BP increases after the procedure
[16] (Figure 1). ‘Belgian Study rains on Renal Denervation
Parade’ wrote an editorialist (http://www.medlatest.com/2013/
06/18/belgian-study-rains-renal-denervation-parade/). Notwith-
standing some other, more critical assessments of the efficacy
and safety of the technique [17, 18], the parade went on
apparently undisturbed until the debacle caused by the an-
nouncement that Symplicity HTN-3 [8] had failed to reach its
primary efficacy endpoint (http://www.tctmd.com/show.aspx?
Id=123265). This news had a devastating impact on the device
industry, leading to definitive or temporary stopping of large
ongoing research programmes (http://www.reuters.com/article/
2014/01/24/us-covidien-divestment-idUSBREA0N18B20140124).
To us, however, the failure of Symplicity HTN-3 [8] was
not a major surprise. We had since long considered this as a
reasonable working hypothesis in view of the multiple weak-
nesses and potential biases of current studies [5, 14, 19, 20]. In
particular, the rationale, mechanism of action, efficacy and
safety of the technique rest on weak and fragmentary evidence.
RENAL DENERVATION: CRITICAL
APPRAISAL OF THE EVIDENCE
Pathophysiological basis of renal denervation
The development of catheter-based RDN was based on
several assumptions [21]: (i) excessive activation of the sym-
pathetic nervous system is a major player in the pathogenesis
of resistant hypertension, (ii) disruption of fibres located
within the adventitia of renal arteries leads to inhibition of the
efferent pathway, with subsequent decrease in salt and water
retention and renin release and increased renal plasma flow,
(iii) part of the benefit of RDN is mediated by disruption of
the afferent pathway, leading to decreased cardiac hypertrophy
and vascular remodelling and (iv) current RDN systems allow
efficient and reproducible inhibition of this bidirectional
traffic, leading to predictable BP responses.
Unfortunately, despite performance of thousands of RDN
procedures worldwide, most data establishing the role of the
sympathetic nervous system in resistant hypertension are still
limited to extrapolation of animal data, indirect evidence
derived from hypothetical pathophysiological processes and
data on file. Direct evidence suggesting an increased contri-
bution of the sympathetic nervous system in resistant versus
controlled or uncontrolled non-resistant hypertension is
lacking. While in Symplicity HTN-1 [1], Krum et al. reported
a 47% decrease (95% CI, 28–65%) in whole-body spill-over of
norepinephrine from baseline to 15–30 days after the pro-
cedure, the effects of RDN on peripheral sympathetic activity
assessed by microneurography and on baroreflex sensitivity
are still controversial [22, 23]. The impact of RDN on salt and
water reabsorption and renal plasma flow also remains undo-
cumented. Furthermore, per-procedural tests allowing to
check the completeness of RDN and to benchmark the repro-
ducibility and efficacy of different renal ablation systems are
currently unavailable. Finally, conditions associated with sym-
pathetic overactivity, such as obesity or renal dysfunction, were
not associated with an increased likelihood of BP improvement
after RDN [5]. On the contrary, preliminary analysis of the
ENCOReD registry [16] shows an inverse association of the BP
response to RDN with serum creatinine and body mass index.
Efficacy of RDN
Given the fact that 24h-ABPM is an independent predictor
of cardiovascular events in patients with resistant hyperten-
sion, while, after adjustment for traditional risk factors, office
F IGURE 1 : Individual responses of systolic (A, C) and diastolic
(B, D) blood pressure on office (A, B) and 24-h ambulatory (C, D)
measurement after renal denervation in 109 patients from the
ENCOReD network. These results highlight the crucial importance
of identification of responder profiles before renal denervation is
considered an established treatment of resistant hypertension
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BP has little predictive value [24], evaluation of the efficacy of
RDN should primarily be based on out-of-the-office BP. Un-
fortunately, 24-h ambulatory BP decrease after RDN was
seldom reported and when available was not always significant
[20]. In larger cohorts [2, 16], it was only one-third of office
BP decrease, compared with the expected two-thirds observed
in drug trials [5]. This discrepancy between office and ambu-
latory BP decrease after RDN likely reflects an overestimation
of the true effect of RDN on office BP due to Hawthorne
effect, regression to the mean and observer-related biases. Fur-
thermore, individual BP responses to RDN are highly variable
[16, 20], with more than one-third of patients experiencing an
increase rather than a decrease in ambulatory BP [16]. Finally,
in a small Norwegian cohort [25] including patients carefully
selected after witnessed intake of drugs, both office and 24-h
ambulatory BP remained unchanged after RDN, raising
further concerns about the residual effect of RDN in drug-
adherent, truly resistant hypertensive patients [20].
Safety of RDN
The Simplicity HTN-1 registry [3, 26] shows a substantial
decrease of estimated glomerular filtration rate (eGFR) 2 and
3 years after RDN. In the absence of a control group and de-
tailed medication history, whether this corresponds to the
natural history of the disease, reflects changes in diuretics and/
or antihypertensive drugs or is due to an effect of RDN per se
remains unclear. Notably also, in the EnligHTN1 trial [27],
eGFR decreased significantly from 87 to 82 mL/min/1.73 m2
6 months after RDN (P = 0.004). The safety of RDN for renal
function remains thus to be demonstrated.
Potential damage to the renal arteries induced by RDN
is another matter of concern. In seven swines euthanized
6 months after RDN [28], the renal arteries showed fibrosis
from 10 to 25% of the total media and the underlying adventi-
tia. In man, optical coherence tomography disclosed diffuse
renal artery constriction and local tissue damage after RDN,
with oedema and thrombus formation at the ablation site [29].
Furthermore, several cases of renal artery stenosis or stenosis
progression have been reported with different catheters [14].
Unfortunately, evaluation of renal arteries in Symplicity
HTN- 2 [2] was limited to renal duplex in most cases (37/43)
and was also suboptimal in the Symplicity HTN-1 registry [3].
In the absence of systematic, state-of-the-art renal artery
imaging in randomized studies, the incidence and prognosis of
renal artery stenosis post-RDN remain to be established.
Rationale underlying widespread use of RDN
Besides efficacy and safety of the procedure, the rationale
underlying a widespread use of RDN in drug-resistant hy-
pertension rests on several assumptions: (i) drug-resistant hy-
pertension is frequent, (ii) in most patients with resistant
hypertension, BP control cannot be achieved by drugs and (iii)
a large proportion of patients with resistant hypertension are
eligible for the procedure.
A short review of the evidence shows that none of these
claims is justified. Indeed, while the prevalence of apparently
resistant hypertension is estimated to be 10–15% of the treated
hypertensive population [5], exclusion of patients with white-
coat resistant hypertension (∼30–40%) [30] and poor treat-
ment adherence (up to 50%) would lead to a much lower
proportion. Furthermore, as demonstrated in a multicentre
cohort of 731 patients, a substantial proportion of patients
with resistant hypertension can reach BP control after skilful
treatment adjustment in expert centres, removing the indi-
cation of RDN [31]. Finally, many other patients do not
qualify for RDN due to secondary hypertension, morbid
obesity or unsuitable renal anatomy, dramatically reducing the
proportion of patients eventually amenable to RDN [32–33].
Mov ing ahead
The story of RDN uncontrolled deployment in the absence of
solid evidence of efficacy and safety raises concerns. It shows
what happens when scientists and health authorities cannot
assume their responsibility in a concerted way, leaving the way
open for market-driven, short view strategies, and thus exposing
thousands of patients to unnecessary and potentially harmful
procedures. We now know that the giant had feet of clay, as the
sole announcement of the failure of Symplicity HTN-3 [8] to
reach its primary endpoint proved sufficient to put a stop to large
and costly industry-driven research programmes, even before the
results of the trial were in the public domain.
Does this mean the end of RDN? In no way. Rather, it points
to the urgent need for more and better evidence [14] before
further clinical application of the technique. RDN is not—and
probably will never be—the standard treatment for all patients,
whose BP remains uncontrolled on triple antihypertensive
therapy. From a public health perspective, it may prove more
cost-effective to promote education of both patients and phys-
icians and improve drug treatment and drug adherence. Indeed,
as previously discussed, in expert hands, most patients with diffi-
cult-to-treat or resistant hypertension can achieve BP control.
Furthermore, a substantial proportion of those who remain un-
controlled will not qualify for RDN, due to irreversibly stiffened
arteries, advanced renal failure or unsuitable renal anatomy. Still,
the technique may prove efficient and safe in a subset of patients
in whom all efforts to obtain BP control failed.
To identify potential responders to RDN, using state-of-
the-art end points and methods to evaluate safety and efficacy,
we designed the INSPiRED randomized controlled trial
(NCT01505010) [34]. Compared with previous and ongoing
trials, INSPiRED has unique features: (i) exclusion of patients
with chronic kidney disease stage 3 (<60 mL/min/1.73 m2)
and/or isolated systolic hypertension, (ii) age limit <70 years,
(iii) drug treatment optimization with systematic assessment
of adherence throughout study, use of single-pill combinations
including up to three antihypertensive agents and long-acting
‘forgiving’ drugs, (iv) state-of-the-art renal artery imaging by
magnetic resonance or preferably computerized tomographic
angiography, (v) validation of urinary proteomic biomarkers
to predict BP responses and changes in renal function, (vi)
out-of-the-office BP for patient selection and follow-up, (vii)
safety assessment based on glomerular filtration rate estimated
according to both Chronic Kidney Disease Epidemiology Col-
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(viii) extension of the follow-up beyond 6 months up to 3
years to assess the incidence of morbidity and mortality, (ix)
use of RDN systems with a design different from the Sympli-
city catheter and (x) use of heart rate variability in all patients
and renal nerve stimulation in selected centres to assess the
completeness of RDN acutely and chronically. Along with
other randomized trials, such as the Oslo RDN (NCT0167
3516) and DENER-HTN (NCT01570777) trials, INSPiRED
will provide decisive information on safety, efficacy and cost-
effectiveness of RDN, and by doing so inform guideline com-
mittees and health policy-makers. In the meantime, RDN
should remain the ultima ratio in truly resistant hypertensive
patients, preferably in a research context [5].
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